{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-051681","form_type":"8-K","ticker":"KTTA","cik":"0001841330","company_name":"Pasithea Therapeutics Corp.","filed_at":"2026-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.095666+00:00","generated_at":"2026-05-15T00:02:18.000717+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Pasithea Therapeutics appoints Kartik Krishnan as Chief Medical Officer, effective May 1, 2026","bullets":["Dr. Krishnan appointed CMO effective May 1; will lead PAS-004 clinical strategy for NF1-associated neurofibromas.","Over 20 years of experience; previously CMO at Arcus Biosciences, contributed to cobimetinib approval for melanoma.","Employment agreement: $500k base salary, 40% bonus eligibility, and options for 1.13M shares at $0.841 exercise price.","CEO Tiago Reis Marques granted options for 1.76M shares; other execs/employees received 1.24M shares in aggregate.","Non-employee directors each receive options for 152,783 shares, vesting over one year."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-051681","json":"https://secwatch.observer/filing/0001213900-26-051681.json","markdown":"https://secwatch.observer/filing/0001213900-26-051681.md","text":"https://secwatch.observer/filing/0001213900-26-051681.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1841330/000121390026051681/0001213900-26-051681-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1841330/000121390026051681/ea0288864-8k_pasithea.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T00:02:18.000717+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4399391cb7","claim":"Kartik Krishnan was appointed as Chief Medical Officer at Pasithea Therapeutics Corp..","evidence_excerpt":"On May 4, 2026, Pasithea Therapeutics Corp. (the “Company”) announced the appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer of the Company, effective May 1, 2026.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1841330/000121390026051681/0001213900-26-051681-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}